
A Cancer Patient Chose Assisted Death. That Wasn't the Last Hard Choice.
'A year ago I was diagnosed with a terminal lung cancer,' she began, 'one that's incurable, catastrophic, all the terrible adjectives.' She gave a small laugh, acknowledging the whole thing sounded preposterous.
The air in the packed conference room went still.
Ms. Andia, 44, a professor and a former official in Colombia's health ministry, said she was going to speak not as an expert, but from a different perspective, one newly acquired — that of a patient. A particular health rights issue preoccupied her these days, she said: the right to death.
No one, she went on, wants to talk to me about dying.
She began to speak faster and faster, and her hands fluttered around her face like small birds. People in the audience looked at the floor, the ceiling, their laps.
'How come we can't talk about having a dignified death when we talk about the right to health?' she demanded.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Gaza hostages Evyatar David, Rom Braslavski lost 50% of body weight, medical report says
The report is based on recent documentation, which includes images of David and Braslavski showing extreme malnutrition as well as testimonies and medical data from survivors. The Health Division of theHostages' Families Forum on Monday published a comprehensive medical report warning that the hostages in Gaza are suffering from intentional, ongoing, and systematic starvation. This advanced state of hunger has reportedly caused severe multi-systemic damage, placing them at immediate risk of death. The report is based on recent documentation, which includes images of Evyatar David and Rom Braslavski showing extreme malnutrition, testimonies from survivors, medical data from these survivors, and pathological reports of hostages who have been murdered. According to the testimonies, the food provided to the hostages has been minimal, lacking essential nutritional values. In some cases, the ration consisted of half a pita per day or less. Hostages have reported prolonged hunger, days without food, constant exhaustion, and food distribution used as a form of punishment. The latest video from Evyatar David, in which he shows his meager meals, directly aligns with these testimonies. Weight assessments conducted by experienced clinical dietitians and Professor Ronit Endovert, former head of the Nutrition Division at the Health Ministry, indicate that David's weight has decreased by approximately 41%, from his original weight to 45-40 kg. Rom Braslavski, who began with a body mass at the lower threshold, is also at risk of further weight loss. His current weight is estimated to be 47-43 kg, a decrease of around 31%. Both men suffer from severe malnutrition, which the World Health Organization defines as a high clinical risk for complications, even death. The process of extreme starvation The extreme starvation they are experiencing is a dangerous process in which the body first breaks down fat, then muscle mass, and eventually vital tissues, including the heart muscle. When fat levels drop below 5%, there is a real risk of heart failure, kidney failure, arrhythmia, system collapse, and sudden death. The report also describes the phenomenon of the "starving brain," resulting in severe neuropsychological damage from prolonged malnutrition. This includes memory impairment, cognitive decline, depression, confusion, apathy, and, in some cases, hallucinations. The term "starving brain" refers to widespread damage to the nervous system caused by deficiencies in glucose, essential vitamins, and amino acids. Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Brazil, Japan beef talks focus on smaller Brazilian states, upsetting industry
By Ana Mano and Marcela Ayres SAO PAULO (Reuters) -Ongoing talks to open the Japanese market to Brazilian beef are focusing on supplies from three small Brazilian exporting states, upsetting other parts of the South American country's industry that are eager to reach the high-paying customers, according to multiple sources. Brazil, the world's biggest beef exporter, has tried for two decades to crack the Japanese market without success. A deal would give Japan an alternative to its top suppliers, the United States and Australia, at a time when U.S. tariffs are reshaping global food trade. Negotiations gained momentum after a state visit of Brazil's President Luiz Inacio Lula da Silva in March to Japan, one of the world's largest beef importers. But the current state of talks, which focus on states representing less than 4% of Brazil's exports by volume, worries meatpackers in the big beef-producing states of Sao Paulo, Mato Grosso, Mato Grosso do Sul, and Para. Together, they accounted for nearly 60% of Brazil's total beef exports, or 1.72 million metric tons last year. A Brazilian government memo, issued after a technical visit by Japanese officials in June, showed Brasília answered "a questionnaire for the import of beef from the southern part of the Republic Federation of Brazil," naming Rio Grande do Sul, Parana, and Santa Catarina. Those three small exporting states were declared free of foot-and-mouth, a contagious viral disease in cattle, earlier than the other states, although Brazil acquired in May the national status of being free of the disease without vaccination from the World Organization for Animal Health. Brazil's last outbreak of the disease was in 2006, according to the government. The Brazilian Agriculture Ministry did not have an immediate comment on its talks with Japan. A local government source, who asked not to be named, confirmed talks were taking place by region. The person said Brazil initially has no plans to negotiate permits beyond the three states. Beef sector representatives, including exporters, told Reuters they hope more states will be included. "We know talks are difficult," said Paulo Mustefaga, head of beef lobbying group Abrafrigo, which represents Marfrig and smaller beef exporters. "The surprise for us is that this is now moving towards approval for only three states." Japan's Ministry of Agriculture, Forestry and Fisheries said it was aware of Brazil's status of being free of foot-and-mouth disease. It added that Japan is "conducting a risk assessment in accordance with Japanese procedures" ahead of issuing any export permits to Brazilian meatpackers, without elaborating. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson's disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson's disease. In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal") for the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America. In July 2025, Knight announced that CREXONT® submission was accepted for review by Health Canada. 'This submission of CREXONT® in Mexico demonstrates Knight's continued execution of our strategy to expand our neurology portfolio,' said Samira Sakhia, President and Chief Executive Officer of Knight. 'There is a high unmet medical need in the treatment of Parkinson's disease, and we are confident that, with CREXONT®, we will be bringing a much-needed novel treatment option to Parkinson's patients.' About CREXONT® CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) capsule that combines both immediate-release granules and extended-release beads for the treatment of Parkinson's disease. CREXONT® contains immediate-release (IR) granules and extended-release (ER) coated beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated with a sustained release polymer to allow for gradual drug release, a mucoadhesive polymer designed to prolong adhesion at absorption site, and an enteric coating to prevent the granules from disintegrating prematurely in the stomach. CREXONT® was studied in the RISE-PD clinical study which was a 20-week, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial with 630 patients. The RISE-PD study successfully met its primary and secondary endpoints, demonstrating that treatment with CREXONT® significantly improved daily "Good On" time with fewer doses compared to IR CD/LD. Specifically, CREXONT® showed an improvement of 0.53 hours (least squares mean, 95% CI, 0.09-0.97), with an average dosing frequency of three times per day versus five times per day for IR CD/LD1. A post-hoc analysis of the primary endpoint on a per dose basis showed 1.55 more hours of 'Good On' time per dose of CREXONT, compared to IR CD/LD.2 About Parkinson's disease Parkinson's disease has become the fastest growing neurological disorder worldwide, with approximately 1 million patients diagnosed in the U.S.3,4 In Mexico, the Parkinson's Movement Disorders Clinic at Manuel Velasco Suárez National Institute of Neurology and Neurosurgery estimates that 500,000 people between the ages of 45 and 60 are affected by the illness5. Parkinson's disease is characterized by slowness of movement, stiffness, resting tremor and impaired balance6. While Parkinson's disease is not considered a fatal disease, it is associated with significant morbidity and disability7. The average age at diagnosis for patients with Parkinson's disease is 60; as people live longer, the number of patients living with Parkinson's disease is predicted to grow significantly over the coming decades.3,8 About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. References 1 Hauser RA et al. JAMA Neurol. 2023 Oct 1;80(10):1062-1069.2 Hauser RA et al. Neurology 2022;98 (supplement 18).3 Dorsey ER et al. JAMA Neurol. 2018;75(1):9-10.4 Marras et al. NPJ Parkinsons Dis. 2018;4:21.5 Secretaría de Salud. Enfermedad de Parkinson, segundo lugar entre los padecimientos neurodegenerativos. Gobierno de México. Published April 11, 2018. Accessed March 27, 2025. NINDS. Parkinson's disease: challenges, progress, and promise. Reviewed August 2019. Accessed April 16, 2021.7 Data Monitor: Gibrat et al., 2009; Goldenberg, 2008; Muangpaisan et al., 2009; Pringsheim et al., 2014.8 John Hopkins Medicine. Young-Onset Parkinson's disease. Accessed August 17, 2021. CONTACT INFORMATION: Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: in to access your portfolio